Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q5XG87

UPID:
PAPD7_HUMAN

ALTERNATIVE NAMES:
DNA polymerase sigma; LAK-1; Non-canonical poly(A) RNA polymerase PAPD7; PAP-associated domain-containing protein 7; TRAMP-like complex polyadenylate polymerase; Terminal guanylyltransferase; Terminal uridylyltransferase 5; Topoisomerase-related function protein 4-1

ALTERNATIVE UPACC:
Q5XG87; A0A0X1KG68; A8K1E2; M1JCE6; O43289; Q17RZ1; Q9Y6C1

BACKGROUND:
The enzyme Terminal nucleotidyltransferase 4A, also referred to as TRAMP-like complex polyadenylate polymerase and Terminal guanylyltransferase, is pivotal in mRNA stabilization. By preferentially transferring ATP and GTP on RNA 3' poly(A) tails, it shields mRNAs from active deadenylation. Its absence of terminal uridylyltransferase activity distinguishes it from other nucleotidyltransferases, underscoring its unique function in the RNA life cycle and post-transcriptional regulation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Terminal nucleotidyltransferase 4A unveils promising avenues for the development of novel therapeutic interventions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.